These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 27149976)

  • 1. Effect of non-invasive prenatal testing as a contingent approach on the indications for invasive prenatal diagnosis and prenatal detection rate of Down's syndrome.
    Kou KO; Poon CF; Kwok SL; Chan KY; Tang MH; Kan AS; Leung KY
    Hong Kong Med J; 2016 Jun; 22(3):223-30. PubMed ID: 27149976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency.
    Orlandi F; Damiani G; Hallahan TW; Krantz DA; Macri JN
    Ultrasound Obstet Gynecol; 1997 Dec; 10(6):381-6. PubMed ID: 9476320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective clinical trial to compare the performance of dried blood spots prenatal screening for Down's syndrome with conventional non-invasive testing technology.
    Hu H; Jiang Y; Zhang M; Liu S; Hao N; Zhou J; Liu J; Zhang X; Ma L
    Exp Biol Med (Maywood); 2017 Mar; 242(5):547-553. PubMed ID: 28056555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters.
    Wald NJ; Watt HC; Hackshaw AK
    N Engl J Med; 1999 Aug; 341(7):461-7. PubMed ID: 10441601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A.
    Haddow JE; Palomaki GE; Knight GJ; Foster DL; Neveux LM
    J Med Screen; 1998; 5(3):115-9. PubMed ID: 9795869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    BJOG; 2004 Jun; 111(6):521-31. PubMed ID: 15198778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units.
    Chitty LS; Wright D; Hill M; Verhoef TI; Daley R; Lewis C; Mason S; McKay F; Jenkins L; Howarth A; Cameron L; McEwan A; Fisher J; Kroese M; Morris S
    BMJ; 2016 Jul; 354():i3426. PubMed ID: 27378786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of the integrated test in the Down's syndrome screening algorithm.
    Springer D; Loucky J; Tesner P; Cutka D; Stejskal D; Gregor V; Zima T
    J Med Screen; 2018 Sep; 25(3):114-118. PubMed ID: 29575979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
    Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
    J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group.
    Piggott M; Wilkinson P; Bennett J
    J Med Screen; 1994 Jan; 1(1):45-9. PubMed ID: 8790485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SURUSS in perspective.
    Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
    Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antenatal screening for Down's syndrome.
    Wald NJ; Kennard A; Hackshaw A; McGuire A
    J Med Screen; 1997; 4(4):181-246. PubMed ID: 9494915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong.
    Lam YH; Ghosh A; Tang MH; Tang LC; Lee CP; Sin SY; Ho PK
    Prenat Diagn; 1998 Jun; 18(6):585-89. PubMed ID: 9664604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prenatal screening: the example of Down's syndrome screening].
    Donner C; Daelemans C; Ceysens G
    Rev Med Brux; 2015 Sep; 36(4):207-11. PubMed ID: 26591302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing outcomes and costs between contingent and combined first-trimester screening strategies for Down's syndrome.
    Martín I; Gibert MJ; Aulesa C; Alsina M; Casals E; Bauça JM
    Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():13-8. PubMed ID: 25827079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal serum screening in Ontario using the triple marker test.
    Summers AM; Farrell SA; Huang T; Meier C; Wyatt PR
    J Med Screen; 2003; 10(3):107-11. PubMed ID: 14561260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
    Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
    Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second trimester screening for Down's syndrome: 7 years experience.
    Beaman JM; Goldie DJ
    J Med Screen; 2001; 8(3):128-31. PubMed ID: 11678551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of a regional screening programme using maternal serum alpha fetoprotein (AFP) and human chorionic gonadotrophin (hCG) on the birth incidence of Down's syndrome in the west of Scotland.
    Crossley JA; Aitken DA; Berry E; Connor JM
    J Med Screen; 1994 Jul; 1(3):180-3. PubMed ID: 8790513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antenatal screening for Down's syndrome with the quadruple test.
    Wald NJ; Huttly WJ; Hackshaw AK
    Lancet; 2003 Mar; 361(9360):835-6. PubMed ID: 12642052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.